Medicare Enrolled
Dr. Vijay Sandilya, M.D.
Hematology & Oncology · Egg Harbor Twp, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sandilya from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sandilya?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sandilya
Dr. Vijay Sandilya is a hematology & oncology specialist in Egg Harbor Twp, NJ, with 16 years of NPI registration. Based on federal Medicare data, Dr. Sandilya performed 3,628 Medicare services across 742 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sandilya received a total of $10,894 from 85 pharmaceutical and/or device companies across 707 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sandilya is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice
▲ Top 38% volume in NJ
$10,894 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,628
Medicare services
Top 38% in NJ for hematology & oncology
742
Unique beneficiaries
$32
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~227 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 1,260 | $18 | $50 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
1,040 | $6 | $50 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
195 | $8 | $30 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
144 | $103 | $700 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
137 | $104 | $199 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
123 | $42 | $95 |
| Anti-nausea injection (Aloxi/palonosetron) | 120 | $1 | $50 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
108 | $145 | $448 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
100 | $73 | $150 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
91 | $67 | $169 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
64 | $12 | $70 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
46 | $118 | $300 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
42 | $14 | $75 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
42 | $66 | $150 |
| New patient office visit, complex (60-74 min) | 30 | $141 | $536 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
21 | $26 | $98 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
18 | $110 | $323 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
17 | $58 | $200 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
17 | $126 | $300 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
13 | $119 | $351 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.3% high complexity
74.8% medium
22.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,894
Total received (2018-2024)
Avg $1,556/year across 7 years
Top 26% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
85
Companies
707
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,725 (98.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$155 (1.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$13 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,255
2023
$2,316
2022
$2,312
2021
$1,600
2020
$702
2019
$1,170
2018
$539
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$300
PFIZER INC.
$260
Celgene Corporation
$186
Daiichi Sankyo Inc.
$177
Gilead Sciences, Inc.
$157
Janssen Biotech, Inc.
$153
GlaxoSmithKline, LLC.
$99
Eisai Inc.
$75
Tempus AI, Inc
$75
Genmab U.S., Inc.
$73
Astellas Pharma US Inc
$58
Stemline Therapeutics Inc.
$51
Lilly USA, LLC
$46
Exelixis Inc.
$45
Incyte Corporation
$44
ABBVIE INC.
$37
Merck Sharp & Dohme LLC
$37
Rigel Pharmaceuticals, Inc.
$36
Mirati Therapeutics, Inc.
$34
Immunocore Limited
$33
Regeneron Healthcare Solutions, Inc.
$30
E.R. Squibb & Sons, L.L.C.
$29
Sumitomo Pharma America, Inc.
$29
Spectrum Pharmaceuticals Inc.
$24
Alexion Pharmaceuticals, Inc.
$20
Agios Pharmaceuticals, Inc.
$19
ARRAY BIOPHARMA INC
$18
Geron Corporation
$18
SOBI, INC
$17
SERVIER PHARMACEUTICALS LLC
$17
TerSera Therapeutics LLC
$16
PUMA BIOTECHNOLOGY, INC.
$15
Celltrion USA Inc.
$14
Karyopharm Therapeutics Inc.
$14
Top 3 companies account for 33.1% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$834
E.R. Squibb & Sons, L.L.C.
$813
Janssen Biotech, Inc.
$646
Celgene Corporation
$586
PFIZER INC.
$560
Daiichi Sankyo Inc.
$497
Astellas Pharma US Inc
$474
Seagen Inc.
$390
Lilly USA, LLC
$368
Novartis Pharmaceuticals Corporation
$360
Gilead Sciences, Inc.
$319
Genentech USA, Inc.
$317
Eisai Inc.
$309
Incyte Corporation
$285
Merck Sharp & Dohme LLC
$230
Exelixis Inc.
$211
Amgen Inc.
$171
Merck Sharp & Dohme Corporation
$170
Bayer HealthCare Pharmaceuticals Inc.
$164
Pharmacyclics LLC, An AbbVie Company
$152
Regeneron Healthcare Solutions, Inc.
$150
EISAI INC.
$146
GlaxoSmithKline, LLC.
$144
Kite Pharma, Inc.
$133
GENZYME CORPORATION
$123
Janssen Pharmaceuticals, Inc
$118
AVEO Pharmaceuticals, Inc.
$115
Pharmacyclics LLC, an AbbVie Company
$106
Stemline Therapeutics Inc.
$103
Genmab U.S., Inc.
$101
Rigel Pharmaceuticals, Inc.
$96
ARRAY BIOPHARMA INC
$93
MorphoSys, US Inc.
$89
TESARO, Inc.
$86
Ipsen Biopharmaceuticals, Inc
$86
Spectrum Pharmaceuticals Inc.
$76
Tempus AI, Inc
$75
ABBVIE INC.
$74
EMD Serono, Inc.
$68
Mirati Therapeutics, Inc.
$50
G1 Therapeutics, Inc.
$50
TerSera Therapeutics LLC
$48
Pharmacosmos Therapeutics Inc.
$47
Dova Pharmaceuticals
$43
Takeda Pharmaceuticals U.S.A., Inc.
$41
Myriad Genetic Laboratories, Inc.
$38
Agios Pharmaceuticals, Inc.
$35
Aadi Bioscience, Inc.
$34
JAZZ PHARMACEUTICALS INC.
$34
Immunocore Limited
$33
Kyowa Kirin, Inc.
$30
Sumitomo Pharma America, Inc.
$29
Epizyme, Inc.,
$29
AMAG Pharmaceuticals, Inc.
$28
AbbVie, Inc.
$28
Seattle Genetics, Inc.
$27
Foundation Medicine, Inc.
$27
Dendreon Pharmaceuticals LLC
$21
Alexion Pharmaceuticals, Inc.
$20
TAIHO ONCOLOGY, INC.
$18
Geron Corporation
$18
SOBI, INC
$17
SERVIER PHARMACEUTICALS LLC
$17
Pharming Healthcare, Inc.
$16
PUMA BIOTECHNOLOGY, INC.
$15
Novocure Inc.
$15
Boehringer Ingelheim Pharmaceuticals, Inc.
$15
Fresenius Kabi USA, LLC
$14
Celltrion USA Inc.
$14
AbbVie Inc.
$14
Jazz Pharmaceuticals Inc.
$14
Karyopharm Therapeutics Inc.
$14
CTI BioPharma Corp.
$14
Clinigen Inc
$14
Bayer Healthcare Pharmaceuticals Inc.
$14
Coherus Biosciences Inc.
$14
Ferring Pharmaceuticals Inc.
$13
Secura Bio, Inc.
$13
Acrotech Biopharma LLC
$13
Cumberland Pharmaceuticals, Inc.
$13
Advanced Accelerator Applications
$13
Deciphera Pharmaceuticals Inc.
$12
Prometheus Laboratories Inc.
$12
Taiho Oncology, Inc.
$11
Organon LLC
$8
Top 3 companies account for 21.0% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AUGTYRO · Alecensa · Aliqopa · Avastin · BELEODAQ · BOSULIF · BRAC CDx · BRAFTOVI · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CEREZYME · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELZONRIS · ENHERTU · ERBITUX · ERLEADA · Enhertu · Epkinly · Erivedge · Erleada · Ethyol · FARYDAK · FERAHEME · FIRMAGON · FOTIVDA · FOUNDATIONONE · Folotyn · Fyarro · GILOTRIF · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kabiven · Kyprolis · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · NINLARO · Nexavar · NovoTTF-100L · Nplate · Nubeqa · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · ORGOVYX · Orserdu · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · Proleukin · QINLOCK · REBLOZYL · RETEVMO · ROLVEDON · RUCONEST · RYTELO · Revlimid · Rezlidhia · SANDOSTATIN · SARCLISA · SOMATULINE DEPOT · Stivarga · TAGRISSO · TALVEY · TAZVERIK · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Tibsovo · Tivdak · Trodelvy · ULTOMIRIS · Udenyca · VARUBI · VEGZELMA · VENCLEXTA · VERZENIO · VYXEOS · Venclexta · Vonjo · XALKORI · XARELTO · XOSPATA · XPOVIO · XT CDX · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · Zoladex · myChoice CDx
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
13
Per 100K population
4.7
County median income
$76,819
Nearest hospital
SHORE MEDICAL CENTER
5.2 mi
5.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sandilya is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sandilya experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Sandilya performed 1,260 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sandilya receive payments from pharmaceutical companies?
Yes. Dr. Sandilya received a total of $10,894 from 85 companies across 707 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sandilya's costs compare to other hematology & oncology specialists in Egg Harbor Twp?
Dr. Sandilya's average Medicare payment per service is $32. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sandilya) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Egg Harbor Twp
Browse hematology & oncology specialists in Egg Harbor Twp ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology